CA2157376A1 - Vaccine compositions containing 3-o deacylated monophosphoryl lipid a - Google Patents

Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Info

Publication number
CA2157376A1
CA2157376A1 CA002157376A CA2157376A CA2157376A1 CA 2157376 A1 CA2157376 A1 CA 2157376A1 CA 002157376 A CA002157376 A CA 002157376A CA 2157376 A CA2157376 A CA 2157376A CA 2157376 A1 CA2157376 A1 CA 2157376A1
Authority
CA
Canada
Prior art keywords
vaccine compositions
monophosphoryl lipid
compositions containing
deacylated monophosphoryl
deacylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002157376A
Other languages
French (fr)
Other versions
CA2157376C (en
Inventor
Pierre Hauser
Pierre Voet
Moncef Slaoui
Nathalie Marie-Josephe Garcon-Johnson
Pierre Desmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Pierre Hauser
Pierre Voet
Moncef Slaoui
Nathalie Marie-Josephe Garcon-Johnson
Pierre Desmons
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939306029A external-priority patent/GB9306029D0/en
Priority claimed from GB9403417A external-priority patent/GB9403417D0/en
Application filed by Pierre Hauser, Pierre Voet, Moncef Slaoui, Nathalie Marie-Josephe Garcon-Johnson, Pierre Desmons, Smithkline Beecham Biologicals S.A. filed Critical Pierre Hauser
Priority to CA002555911A priority Critical patent/CA2555911C/en
Priority claimed from PCT/EP1994/000818 external-priority patent/WO1994021292A1/en
Publication of CA2157376A1 publication Critical patent/CA2157376A1/en
Application granted granted Critical
Publication of CA2157376C publication Critical patent/CA2157376C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Novel vaccine compositions comprising small particles of 3-O-deacylated monophosphoryl lipid A are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior immunological properties.
CA002157376A 1993-03-23 1994-03-14 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a Expired - Lifetime CA2157376C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002555911A CA2555911C (en) 1993-03-23 1994-03-14 Adjuvant compositions containing 3-o deacylated monophosphoryl lipid a

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9306029.1 1993-03-23
GB939306029A GB9306029D0 (en) 1993-03-23 1993-03-23 Vaccine compositions
GB9403417.0 1994-02-23
GB9403417A GB9403417D0 (en) 1994-02-23 1994-02-23 Vaccine compositions
PCT/EP1994/000818 WO1994021292A1 (en) 1993-03-23 1994-03-14 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002555911A Division CA2555911C (en) 1993-03-23 1994-03-14 Adjuvant compositions containing 3-o deacylated monophosphoryl lipid a

Publications (2)

Publication Number Publication Date
CA2157376A1 true CA2157376A1 (en) 1994-09-29
CA2157376C CA2157376C (en) 2006-10-31

Family

ID=37394902

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002157376A Expired - Lifetime CA2157376C (en) 1993-03-23 1994-03-14 Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Country Status (1)

Country Link
CA (1) CA2157376C (en)

Also Published As

Publication number Publication date
CA2157376C (en) 2006-10-31

Similar Documents

Publication Publication Date Title
AU2001228521A1 (en) IR absorbing compositions
CA2152615A1 (en) Atovaquone pharmaceutical compositions
EP1388522A3 (en) Colloidal borosilicates and their use in the production of paper
AU8030691A (en) Detergent compositions in the form of tablets
AU8030491A (en) Detergent compositions in the form of tablets
CA2059432A1 (en) Surface modified drug nanoparticles
AU4684989A (en) Certified weigher-short paid mail
CA2217178A1 (en) Vaccines containing a saponin and a sterol
AU5072890A (en) Fungal formulation for biocontrol of soilborne plant pathogens
EP0765163B8 (en) Adjuvant compositions comprising a mineral salt and another immunostimulating compound
CA2045223A1 (en) Surfactant blends useful as a pesticide adjuvants
AU2616192A (en) Perfume particles
AU7890487A (en) Impact resistant polymeric compositions and process for the preparation thereof
CA2151967A1 (en) Magnetic nanocomposite compositions and processes for the preparation and use thereof
AU5279393A (en) Excipient having high compactability and prccess for preparing the same
CA2004723A1 (en) Fatty compositions with high solids content
CA2177668A1 (en) Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant
AU2951489A (en) Improving the stability of pharmaceutical compositions
CA2177667A1 (en) Mammalian vaccine compositions comprising squalene or squalane, lecithin and a polyoxyethylene sorbitan ester as an adjuvant
AU644409B2 (en) Cross-linkable polyester/isocyanate compositions suited for the preparation of composite materials
CA2111758A1 (en) Personal Care Compositions
AU2963889A (en) Easily dispersible psyllium compositions
AU7628391A (en) Conditioning shampoo compositions
AU657334B2 (en) Anti-glaucoma compositions
CA2157376A1 (en) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140314